TNGX
HealthcareTango Therapeutics, Inc. · Biotechnology · $2B
What is Tango Therapeutics, Inc.?
Tango Therapeutics is a clinical-stage biotechnology company focused on discovering and developing targeted cancer therapies. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company applies a synthetic lethality approach to oncology drug discovery.
Tango Therapeutics identifies genetic vulnerabilities in cancer cells and designs small molecule drugs that exploit those weaknesses. Its lead asset, TNG908, targets cancers with a specific chromosomal deletion known as MTAP loss. The company also advances programs targeting BRCA1/BRCA2-mutant cancers and STK11-mutant cancers. A strategic collaboration with Gilead Sciences supports the discovery, development, and potential commercialization of its oncology pipeline.
Tango Therapeutics was founded in 2017 and operates out of Cambridge, Massachusetts.
- TNG908 — synthetic lethal inhibitor targeting MTAP-deleted cancers
- USP1 inhibitor program for BRCA1/BRCA2-mutant cancers
- Target 3 program for STK11-mutant cancers
- Strategic oncology collaboration with Gilead Sciences
Is TNGX a Good Stock to Buy?
UQS Score rates TNGX as Poor overall, reflecting significant challenges across multiple evaluation pillars.
The Risk pillar stands out as the relative bright spot in TNGX's profile, suggesting the company carries a more manageable near-term risk profile than many clinical-stage peers. The Growth pillar registers as Neutral, indicating the pipeline's potential is acknowledged but not yet a clear differentiator.
Both the Quality and Moat pillars score Weak, consistent with a pre-revenue biotech lacking established commercial products or durable competitive advantages. Valuation is rated Elevated, meaning the current price reflects significant optimism relative to the company's fundamentals.
See the complete pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TNGX pay dividends?
No — Tango Therapeutics, Inc. does not currently pay a dividend.
Tango Therapeutics does not pay a dividend, which is typical for clinical-stage biotechnology companies. Available capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions. Investors in TNGX are generally seeking long-term value from drug development outcomes rather than income.
When does TNGX report earnings?
Tango Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, Tango's quarterly reports center on pipeline progress, cash runway, and collaboration milestones rather than product revenue. Key items to watch include clinical trial updates for TNG908 and activity under the Gilead collaboration.
For the most recent quarter's results and upcoming reporting dates, visit Tango Therapeutics' investor relations page directly.
TNGX Price History
+147.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Tango Therapeutics, Inc.?
Based on Tango Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TNGX Long-term Outlook
Tango's fundamental outlook is shaped by binary clinical events rather than steady revenue growth. The Neutral Growth pillar suggests the pipeline carries meaningful but uncertain upside, while the Elevated Valuation pillar indicates the market has already priced in a degree of success. The Weak Quality and Moat pillars reflect the absence of commercial revenue and proprietary barriers that would support a more durable long-term profile. Progress in the Gilead collaboration and clinical readouts for TNG908 are the primary catalysts that could shift the fundamental picture.
Growth drivers
- Clinical advancement of TNG908 in MTAP-deleted cancers
- Milestones and funding from the Gilead Sciences collaboration
- Expansion of the synthetic lethality pipeline into additional oncology indications
Key risks
- Clinical trial failure or disappointing efficacy data for lead programs
- Elevated valuation leaves limited margin of safety if pipeline progress stalls
- Dependence on external collaboration and capital markets to fund operations
TNGX vs Peers
Tango Therapeutics operates in a competitive clinical-stage biotech landscape alongside other specialty therapeutics developers.
Alumis focuses on precision medicine for immune-mediated diseases, pursuing a different therapeutic area than Tango's oncology-centered pipeline.
Arcutis concentrates on dermatological conditions and has advanced products closer to or into commercialization, contrasting with Tango's earlier-stage oncology focus.
Kiniksa targets rare inflammatory diseases, giving it a distinct patient population and regulatory pathway compared to Tango's cancer-focused synthetic lethality approach.
Frequently Asked Questions
What does Tango Therapeutics do?
Tango Therapeutics discovers and develops targeted cancer drugs using a synthetic lethality approach — exploiting specific genetic deletions found in tumor cells. Its lead program, TNG908, targets cancers with MTAP deletions. The company also has programs for BRCA-mutant and STK11-mutant cancers, supported by a collaboration with Gilead Sciences.
Does TNGX pay dividends?
No, Tango Therapeutics does not pay a dividend. As a clinical-stage biotech, the company reinvests available capital into research and clinical development. Dividend payments are not typical for companies at this stage of growth.
When does TNGX report earnings?
Tango Therapeutics reports on a quarterly cadence standard for US-listed companies. Our data source does not cover specific upcoming dates. For the latest schedule and results, check the investor relations section of the Tango Therapeutics website.
Is TNGX a good stock to buy?
UQS Score rates TNGX as Poor overall. The Risk pillar is the relative strength, while Quality, Moat, and Valuation present notable concerns. Whether TNGX fits a portfolio depends on an investor's tolerance for clinical-stage biotech risk. The full pillar breakdown is available to UQS Pro members.
Is TNGX overvalued?
UQS Score rates TNGX's Valuation pillar as Elevated, suggesting the current market price reflects meaningful optimism about pipeline outcomes. For a pre-revenue biotech, valuation is largely driven by clinical expectations rather than current earnings or cash flow.
How does TNGX compare to its competitors?
Compared to peers like Alumis, Arcutis, and Kiniksa, Tango is differentiated by its synthetic lethality platform and oncology focus. Each competitor operates in distinct therapeutic areas. UQS Pro members can view side-by-side pillar comparisons across these names.
What is TNGX's market cap bracket?
Tango Therapeutics is classified as a mid-cap company. This places it in a range that typically attracts both institutional and growth-oriented retail investors, though clinical-stage biotechs at this size carry meaningful binary event risk.
Who founded Tango Therapeutics?
Tango Therapeutics was founded in 2017. Detailed founding history, including the names of founders and early investors, is publicly available through the company's official communications and press archives.
Is TNGX a long-term buy?
As a long-term quality indicator, UQS Score rates TNGX as Poor, driven by Weak Quality and Moat pillars alongside an Elevated Valuation. Long-term outcomes for clinical-stage biotechs hinge heavily on trial results and commercialization milestones rather than current fundamental strength.
What is the main competitive advantage of Tango Therapeutics?
Tango's differentiation lies in its synthetic lethality drug discovery platform, which targets specific genetic vulnerabilities in cancer cells. The Gilead Sciences collaboration adds development resources and validation. However, UQS Score currently rates the Moat pillar as Weak, reflecting the early-stage nature of these advantages.
Is TNGX a growth stock or value stock?
TNGX carries a Neutral Growth pillar and an Elevated Valuation pillar in the UQS framework. That combination suggests the market is pricing in future pipeline success, but current fundamental growth metrics are not yet strong enough to firmly classify it as a growth stock in the traditional sense.
Unlock Full TNGX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics and trend data
- ✓Compare TNGX side-by-side with sector peers
- ✓Screen for higher-quality biotech alternatives
- ✓Get the complete risk and valuation breakdown
Pro Analysis
TNGX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 27.7 | 6.2 | 18.0 | 59.5 | 64.9 | 0.0 | 0.0 |
| May 14, 2026 | 27.7 | 6.2 | 18.0 | 59.5 | 64.8 | 0.0 | -0.5 |
| Apr 2, 2026 | 28.2 | 6.2 | 18.0 | 59.5 | 68.2 | 0.0 | — |
TNGX — Pillar Breakdown
Quality
— 6.2/100 (25%)Tango Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 59.5/100 (20%)Tango Therapeutics, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 64.9/100 (15%)Tango Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Tango Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 18/100 (25%)Tango Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TNGX.
Score Composition
Financial Data
More Stock Analysis
How is the TNGX UQS Score Calculated?
The UQS (Unified Quality Score) for Tango Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Tango Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Tango Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.